Vericel Corporation (VCEL)
NASDAQ: VCEL · Real-Time Price · USD
40.61
+0.37 (0.92%)
Sep 29, 2026, 4:00 PM EDT - Market closed
Vericel Market Cap
Vericel has a market cap or net worth of $2.08 billion as of September 29, 2026. Its market cap has increased by 36.32% in one year.
Market Cap
2.08B
Enterprise Value
2.01B
1-Year Change
36.32%
Ranking
Category
Stock Price
$40.61
ChartMarket Cap Chart
Since December 1, 1998, Vericel's market cap has increased from $31.90M to $2.08B, an increase of 6,418.81%. That is a compound annual growth rate of 16.18%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 29, 2026 | 2.08B | 14.18% |
| Dec 31, 2025 | 1.82B | -32.80% |
| Dec 31, 2024 | 2.71B | 59.48% |
| Dec 29, 2023 | 1.70B | 36.63% |
| Dec 30, 2022 | 1.24B | -32.39% |
| Dec 31, 2021 | 1.84B | 31.15% |
| Dec 31, 2020 | 1.40B | 80.38% |
| Dec 31, 2019 | 777.70M | 3.12% |
| Dec 31, 2018 | 754.20M | 296.53% |
| Dec 29, 2017 | 190.20M | 163.07% |
| Dec 30, 2016 | 72.30M | 17.75% |
| Dec 31, 2015 | 61.40M | -15.08% |
| Dec 31, 2014 | 72.30M | 412.77% |
| Dec 31, 2013 | 14.10M | -74.46% |
| Dec 31, 2012 | 55.20M | -21.48% |
| Dec 30, 2011 | 70.30M | -2.77% |
| Dec 31, 2010 | 72.30M | 35.14% |
| Dec 31, 2009 | 53.50M | -20.74% |
| Dec 31, 2008 | 67.50M | -2.17% |
| Dec 31, 2007 | 69.00M | -53.19% |
| Dec 29, 2006 | 147.40M | -32.17% |
| Dec 30, 2005 | 217.30M | 65.88% |
| Dec 31, 2004 | 131.00M | 38.19% |
| Dec 31, 2003 | 94.80M | 321.33% |
| Dec 31, 2002 | 22.50M | -45.78% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ADMA Biologics | 2.10B |
| Trevi Therapeutics | 2.05B |
| Kodiak Sciences | 2.03B |
| UroGen Pharma | 2.02B |
| Nuvation Bio | 2.02B |
| Recursion Pharmaceuticals | 2.01B |
| Palvella Therapeutics | 1.99B |
| Maravai LifeSciences Holdings | 1.97B |